Millennium Management LLC raised its holdings in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 172.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,973,001 shares of the company’s stock after purchasing an additional 3,147,660 shares during the quarter. Millennium Management LLC’s holdings in Ralliant were worth $253,175,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in RAL. Cetera Investment Advisers purchased a new stake in Ralliant during the second quarter valued at about $700,000. Russell Investments Group Ltd. purchased a new stake in Ralliant during the second quarter valued at about $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in Ralliant during the second quarter valued at about $39,000. First Trust Advisors LP purchased a new stake in Ralliant during the second quarter valued at about $2,013,000. Finally, Federated Hermes Inc. purchased a new stake in Ralliant during the second quarter valued at about $326,000.
Analyst Upgrades and Downgrades
RAL has been the topic of several recent research reports. Truist Financial reaffirmed a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Citigroup upped their price objective on shares of Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Barclays upped their price objective on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Finally, Evercore initiated coverage on shares of Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.30.
Ralliant Trading Down 1.8%
Shares of RAL opened at $67.50 on Thursday. The business’s 50-day moving average price is $54.62 and its 200-day moving average price is $50.26. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $70.22. The stock has a market cap of $7.56 billion and a PE ratio of -6.17. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.
Ralliant (NYSE:RAL – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. The company’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Ralliant Corporation will post 2.64 EPS for the current fiscal year.
Ralliant Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.83%.
Ralliant Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Articles
- Five stocks we like better than Ralliant
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
